MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer

Author:

Kim Suyeon1,Lee Ki Wook1,Yoo Yongjin2,Park Sang Hee1,Lee Ji Won1,Jeon Suhyun3,Illia Shaginyan1,Joshi Pooja4,Park Hyun Woo1,Lo Han-En1,Seo Jimin1,Kim Yeonwoo1,Chang Min1,Lee Tae Jin5,Seo Jong Bae3,Kim Sung-Hak6,Croce Carlo M.4,Kim Inki7,Suh Sung-Suk3,Jeon Young-Jun1

Affiliation:

1. Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea

2. Department of Stem Cell Biology and Regenerative Medicine Institute, Stanford University, Stanford, CA, USA

3. Department of Biosciences, Mokpo National University, Muan, Republic of Korea

4. Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

5. Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA

6. Department of Animal Science, Chonnam National University, Gwangju, Republic of Korea

7. ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea

Funder

SEOK CHUN Research Fund

Hyundai Motor Chung Mong-Koo Foundation

National Research Foundation of Korea

Korea government

Publisher

Informa UK Limited

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3